Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1002280#aggregation> ?p ?o. }
Showing items 1 to 45 of
45
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B405887.
- aggregation creator B405888.
- aggregation creator B405889.
- aggregation creator B405890.
- aggregation creator B405891.
- aggregation creator B405892.
- aggregation creator B405893.
- aggregation creator B405894.
- aggregation creator B405895.
- aggregation creator B405896.
- aggregation creator B405897.
- aggregation creator B405898.
- aggregation creator B405899.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1002280.bibtex.
- aggregation hasFormat 1002280.csv.
- aggregation hasFormat 1002280.dc.
- aggregation hasFormat 1002280.didl.
- aggregation hasFormat 1002280.doc.
- aggregation hasFormat 1002280.json.
- aggregation hasFormat 1002280.mets.
- aggregation hasFormat 1002280.mods.
- aggregation hasFormat 1002280.rdf.
- aggregation hasFormat 1002280.ris.
- aggregation hasFormat 1002280.txt.
- aggregation hasFormat 1002280.xls.
- aggregation hasFormat 1002280.yaml.
- aggregation isPartOf urn:issn:0001-5644.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust Study".
- aggregation abstract "Background and study aims : Large international clinical trials conducted in the past 5 years rapidly improved the treatment of chronic hepatitis C; however, it is unclear whether the advances seen in clinical trials are being paralleled by similar improvements in routine clinical practice. PegIntrust is a Belgian community-based trial evaluating the sustained virological response. Patients and Methods : Observational study of 219 patients receiving pegylated interferon alfa-2b (1.5 mu g/kg/wk) and weight. based ribavirin (800-1200 mg/day) for 48 weeks. Primary study end point was sustained virological response (SVR), defined as undetectable HCV RNA 6 months after the completion of treatment. Results : In total, 108 patients (49.3 %) had undetectable HCV RNA at the end of therapy, 91(41.6%) attaining SVR. Of the 111 patients without an end-of-treatment response, 28 were non-responders, and 21 had virological breakthrough. In total, 134 patients attained early virological response (EVR); 88 (65.7%) of those patients attained SVR. In contrast, 82 (96.5 %) of the 85 patients who did not attain EVR also did not attain SVR. Age, fibrosis score and baseline viral load were identified as important predictors of treatment outcome. The most frequently reported serious adverse events resulting in treatment discontinuation were anemia (n = 10), fatigue/asthenia/malaise (n = 6) and fever (n = 3). Conclusion : Our data indicate that treatment of chronic hepatitis C with PEG-IFN alfa-2b plus weight-based ribavirin results in favourable treatment outcomes in a Belgian cohort of patients treated in community-based clinical practice. (Ada gastroenterol. belg., 2010, 73, 5-11).".
- aggregation authorList BK719417.
- aggregation endPage "11".
- aggregation issue "1".
- aggregation startPage "5".
- aggregation volume "73".
- aggregation aggregates 1002538.
- aggregation isDescribedBy 1002280.
- aggregation similarTo LU-1002280.